APA (7th ed.) Citation

B, F., J, L., D, C., I, L., L, K., A, L., . . . B, A. (2024). French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. British journal of haematology, 205(3), 990. https://doi.org/10.1111/bjh.19505

Chicago Style (17th ed.) Citation

B, Ferment, et al. "French Early Nationwide Idecabtagene Vicleucel Chimeric Antigen Receptor T-cell Therapy Experience in Patients with Relapsed/refractory Multiple Myeloma (FENIX): A Real-world IFM Study from the DESCAR-T Registry." British Journal of Haematology 205, no. 3 (2024): 990. https://doi.org/10.1111/bjh.19505.

MLA (9th ed.) Citation

B, Ferment, et al. "French Early Nationwide Idecabtagene Vicleucel Chimeric Antigen Receptor T-cell Therapy Experience in Patients with Relapsed/refractory Multiple Myeloma (FENIX): A Real-world IFM Study from the DESCAR-T Registry." British Journal of Haematology, vol. 205, no. 3, 2024, p. 990, https://doi.org/10.1111/bjh.19505.